US Edition
News from Financial World
We’ve assigned a media bias rating of unknown to Financial World. You can read more about our methodology here.
Information about Financial World
Where is Financial World located?Financial World's WebsiteFinancial World's TwitterMedia Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Financial World News
Wall Street · New YorkNEW YORK (AP) — Stocks are climbing toward more records on Monday ahead of a week packed with potentially market-moving events for Wall Street. The S&P 500 rose 0.8%. The Dow Jones Industrial Average was up 210 points, or 0.4%, as of 9:35 a.m. Eastern time, and the Nasdaq composite was 1.3% higher. All are adding to their latest all-time highs set on Friday. Stocks also rallied in Asia ahead of a meeting on Thursday between the heads of the Unit…See the Story
Wall Street Rallies Toward More Records as Gold's Price Slumps Again
58% Center coverage: 79 sources
Donald Trump · United StatesPresident Trump said on Monday that he would “love to meet” with North Korean leader Kim Jong Un during his trip to Asia this week. “I’d love to meet with him if he’d like to meet. I got along great with Kim Jong Un. I liked him. He liked me,” Trump told reporters aboard Air Force One while en route to Japan. “If he wants to meet, I’ll be in South Korea.”See the Story
Trump says he'd be willing to extend Asia trip to meet with North Korea's Kim Jong Un
44% Right coverage: 27 sources
PharmaAvidity Biosciences brings to Novartis three RNA therapies in pivotal testing for rare neuromuscular diseases along with the technology that produced them. This platform develops drugs in a new class of targeted medicines offering potential to expand the delivery of RNA treatments beyond the liver. The post Novartis Continues RNA & Neuroscience Growth Strategy With $12B Avidity Bio Acquisition appeared first on MedCity News.See the Story
Novartis Continues RNA & Neuroscience Growth Strategy With $12B Avidity Bio Acquisition
Coverage: 5 sources
